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Aim Statins are known to reduce cardiovascular events in atherosclerotic
patients. Given the experimental protective effect of BAs against atheroscle-
rosis, the aim of this preliminary study was to dertermine the total BAs con-
centration in sera after statins administration. 
Methods Between January 2015 and April 2015, patients hospitalized for a
coronary angiogram and starting a statins treatment for coronary atheroma were
included. Exclusion criteria were post cardiac arrest, non-fasting status, hepatic
disease, antibiotics and corticosteroids. The total BAs concentration was mea-
sured before and 1 month after the initiation of statin therapy by liquid chroma-
rography mass spectrometry. Wilcoxon test was used for statistical analysis. 
Results On a cohort of 360 patients, 37 were eligible and 17, aged of
54±9.6 years old have been retrospectively included. 95% were prescribed
with atorvastatin (68% with atorvastatin 40mg). The mean concentration of
the total BAs before statin was 0.68μmol/L (SEM 0.08μmol/L) and 1.37μmol/
L after (SEM 0.21μmol/L) (p=0.013, figure 1). 
Conclusion statins administration is associated with a doubling of circu-
lating BAs after one month of treatment. This raises a question about statins
increasing BAs synthesis by the liver: the deflection of the cholesterol synthesis
by the liver into BAs instead, could participate to the efficacy of statins. This
could theoretically be beneficial by slowing down the atheroma development
through anti-inflammatory effects of BAs on the macrophage of the plaque.
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Background Despite dual antiplatelet treatment with the new P2Y12
platelet receptor antagonists (P2Y12i), major ischemic events are common fol-
lowing ST elevation myocardial infarction (STEMI). 
Objectives To assess separately resistance to aspirin (HPR-aspirin), resis-
tance to P2Y12i (HPR-P2Y12i) and their association during the acute phase
of STEMI in relation to the occurrence of ischemic events.
Methods We included all consecutive patients admitted for STEMI in our
center between January 2013 and December 2013. All patients received a
loading dose followed by a maintenance dose of aspirin (75mg/day) and either
clopidogrel, prasugrel or ticagrelor. Platelet reactivity was assessed 4±1 days
and 75±15 days after admission using light transmission aggregometry (LTA)
with arachidonic acid (AA) and serum Thromboxane-B2 concentration to
assess HPR-aspirin and LTA-ADP and VASP index to assess HPR-P2Y12i.
Major cardiac and cerebrovascular events (MACCE) were recorded during
one year.
Results 106 patients (61years old, 76% male, 20% with diabetes) were
included. STEMI was anterior in 52% and LV ejection fraction at discharge
was 51±9%. At day 4 after STEMI, HPR-aspirin measured by LTA-AA alone
was found in 23% patients and was correlated with serum thromboxane inhi-
bition, HPR-P2Y12i (VASP≥50% and LTA-ADP≥65%) was observed only in
7% and combined resistance was present in 4% of the patients. Diabetes and
age were predictors of HPR-aspirin. The large use of ticagrelor (34%) and pra-
sugrel (50%) explained the low rate of P2Y12i resistance. HPR-aspirin was
persistent 75 days later in 36% patients who were resistance at day 4. At
1 year, 7.9% patients had experienced MACCE. HPR-aspirin alone and HPR
for both aspirin and P2Y12i were significantly associated with MACCE.
Conclusion Aspirin resistance is frequent just after STEMI and is associ-
ated with MACCE especially when associated with P2Y12i resistance.
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Aim To document low-density lipoprotein cholesterol (LDL-C) values
during hospitalization of ACS patients with/without lipid-lowering therapy
(LLT) at admission, and achievement of the ESC LDL-C target (LDL-C
≤70mg/dL) at 4 months following the acute event using data from the French
cohort of the DYSIS IIACS study.
Methods DYSIS IIACS was a multicentre prospective observational cohort
study (recruitment: Oct 2013 to Oct 2014) conducted in 24 coronary care units
in France. Adults hospitalized for an ACS event and who had a lipid panel
measured within 24 hours of admission were consecutively enrolled. Eligible
patients had to be on LLT for ≥3 months or taking no LLT. A telephone
follow-up interview was carried out with patients (or their next of kin) 120±15
days after the index event.
Results Of the 468 patients enrolled, 50.6% had ST-elevation myocardial
infarction/left bundle branch block, 40.8% had non-ST-elevation myocardial
infarction, and 8.5% had unstable angina. Of the 277 (59.2%) patients on LLT
at admission, 25.3% had an LDL-C <70mg/dl (Table). Most patients (96.4%)
were on statin therapy at discharge (mean+SD dose calculated in atorvastatin
49±28mg/day). Non-statin LLT was used in 5.6% patients at discharge (61.5%
with a cholesterol-absorption inhibitor). At 120 days after admission, 50.9%
of ACS patients with follow-up data had achieved the LDL-C target.
Conclusions These observational data from contemporary French clinical
practice in coronary care units indicate suboptimal LDL-C control, with a sub-
stantial proportion of very high cardiovascular risk patients presenting with
elevated LDL-C despite taking LLT. Four months after the acute event, half
of the patients (with data) failed to achieve the target, with a large difference
between mean value and target LDL-C. 
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